title: Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.
abstract: OBJECTIVE
  Cilostazol may be effective in dementia associated with a cerebral ischaemia. In this study, we examined whether it exerts beneficial effects on learning and/or memory impairment induced by Aβ(25-35) in mice, and compared its effects with those of aspirin.
  
  
  METHODS
  Aβ(25-35) (9 nmol) was administered to mice i.c.v. Learning and memory behaviour were evaluated by measuring spontaneous alternation in a Y-maze and a step-down type passive avoidance test, on the 5th and 8th days after injection respectively. Levels of lipid peroxidation (malondialdehyde) and cytokines in the frontal cortex and hippocampus were measured 2, 3, 5 and 7 days after the Aβ(25-35) injection. The effects of repeated administration of cilostazol and aspirin (both at 30 and 100 mg·kg(-1), p.o.) on any changes induced by Aβ(25-35) were evaluated.
  
  
  RESULTS
  Repeated administration of cilostazol significantly attenuated the impairment of spontaneous alternation and the shortened step-down latency induced by Aβ(25-35) . Aspirin did not show any beneficial effect. A significant increase in the levels of malondialdehyde (MDA) and IL-1β (only measured in hippocampus) was observed 2, 3 and 5 days after the Aβ(25-35) injection in the frontal cortex and hippocampus. Repeated administration of cilostazol (100 mg·kg(-1)) completely prevented the increase in MDA levels but failed to antagonize the increase in the expression of IL-1β induced by Aβ(25-35).
  
  
  CONCLUSIONS
  These results suggest that the protective effect of cilostazol on Aβ(25-35)-induced memory impairment may be related to oxidative stress in the frontal cortex and the hippocampus.
authors.affiliation: Laboratory of Neuropsychopharmacology, Graduate School of Environmental and Human Sciences, Meijo University, Nagoya, Japan. mhiramt@meijo-u.ac.jp
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hiramatsu
authors.forename: Osanao
authors.initials: O
authors.lastname: Takiguchi
authors.forename: Aki
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Mori
mesh_terms: D000544:Alzheimer Disease / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000009:adverse effects / Q000032:analysis*; D000818:Animals; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001362:Avoidance Learning / Q000187:drug effects; D000077407:Cilostazol; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects*; D010446:Peptide Fragments / Q000009:adverse effects / Q000032:analysis / Q000037:antagonists & inhibitors*; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D016229:Amyloid beta-Peptides; D016207:Cytokines; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D013777:Tetrazoles; C074636:amyloid beta-protein (25-35); D008315:Malondialdehyde; D000077407:Cilostazol; D001241:Aspirin
references.citation: Br J Pharmacol. 1999 Jun;127(3):655-60
references.pmid: 10401555
references.citation: Am J Pathol. 1998 Apr;152(4):871-7
references.pmid: 9546346
references.citation: Trends Pharmacol Sci. 2002 Sep;23(9):426-33
references.pmid: 12237155
references.citation: Br J Pharmacol. 2009 Aug;157(7):1270-7
references.pmid: 19552690
references.citation: Am J Geriatr Psychiatry. 2009 Apr;17(4):353-4
references.pmid: 19307864
references.citation: J Pharmacol Exp Ther. 2002 Feb;300(2):709-15
references.pmid: 11805237
references.citation: Neuroscience. 2009 Aug 18;162(2):525-36
references.pmid: 19426786
references.citation: Behav Brain Res. 2007 Jun 18;180(2):139-45
references.pmid: 17420060
references.citation: Brain Res. 2007 Dec 14;1185:246-55
references.pmid: 17936728
references.citation: Neurobiol Aging. 1998 Jan-Feb;19(1):33-6
references.pmid: 9562500
references.citation: Br J Pharmacol. 2006 Dec;149(8):998-1012
references.pmid: 17057756
references.citation: Neurol Res. 2005 Jul;27(5):483-92
references.pmid: 15978173
references.citation: Neurology. 2008 Jun 10;70(24):2291-8
references.pmid: 18509093
references.citation: Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23
references.pmid: 17956317
references.citation: J Pharmacol Exp Ther. 2009 Jul;330(1):2-12
references.pmid: 19318594
references.citation: Neuropharmacology. 2010 Mar-Apr;58(4-5):774-83
references.pmid: 20035772
references.citation: Brain Res. 2010 Jan 14;1309:66-74
references.pmid: 19883632
references.citation: Acta Pharmacol Sin. 2006 Jun;27(6):651-8
references.pmid: 16723081
references.citation: Br J Pharmacol Chemother. 1957 Mar;12(1):12-5
references.pmid: 13413144
references.citation: Pharmacol Res. 2006 Oct;54(4):261-7
references.pmid: 16822680
references.citation: Stroke. 2005 Apr;36(4):782-6
references.pmid: 15746463
references.citation: J Neurosci. 2007 May 16;27(20):5394-404
references.pmid: 17507561
references.citation: Neuroreport. 2000 Feb 28;11(3):431-5
references.pmid: 10718289
references.citation: J Pharmacol Exp Ther. 2002 Mar;300(3):787-93
references.pmid: 11861782
references.citation: Psychopharmacology (Berl). 1988;94(4):491-5
references.pmid: 2836875
references.citation: Free Radic Biol Med. 1997;23(1):134-47
references.pmid: 9165306
references.citation: Biochem J. 1984 Aug 15;222(1):1-15
references.pmid: 6383353
references.citation: Neurosci Behav Physiol. 2003 Feb;33(2):95-8
references.pmid: 12669778
references.citation: Free Radic Res. 2008 Jul;42(7):633-8
references.pmid: 18654878
references.citation: Jpn J Pharmacol. 2000 Feb;82(2):85-94
references.pmid: 10877525
references.citation: J Alzheimers Dis. 2004 Apr;6(2):159-63
references.pmid: 15096699
references.citation: Psychopharmacology (Berl). 2009 Jul;204(4):705-14
references.pmid: 19263040
references.citation: Eur J Pharmacol. 2000 Apr 28;395(2):149-56
references.pmid: 10794821
references.citation: Acta Neurol Scand. 2001 Mar;103(3):166-74
references.pmid: 11240564
references.citation: Lancet. 1997 Nov 15;350(9089):1476-7; author reply 1477
references.pmid: 9371189
references.citation: J Pharmacol Exp Ther. 2004 Mar;308(3):896-903
references.pmid: 14634032
references.citation: Arzneimittelforschung. 1985;35(7A):1144-9
references.pmid: 4074426
references.citation: Stroke. 2006 Jun;37(6):1539-45
references.pmid: 16645134
references.citation: Am J Pathol. 1999 Sep;155(3):863-8
references.pmid: 10487843
references.citation: Brain Res. 1996 Jan 15;706(2):181-93
references.pmid: 8822355
references.citation: J Neurochem. 2008 Oct;107(1):197-207
references.pmid: 18680556
references.citation: Brain Res. 2006 Apr 12;1082(1):182-91
references.pmid: 16516167
references.citation: FASEB J. 2001 Jun;15(8):1407-9
references.pmid: 11387239
references.citation: J Neurosci. 2001 Jun 15;21(12):4183-7
references.pmid: 11404403
references.citation: J Pharmacol Exp Ther. 2008 Oct;327(1):137-47
references.pmid: 18621989
references.citation: Brain Res. 2000 Mar 24;859(2):303-10
references.pmid: 10719078
references.citation: Eur J Pharmacol. 1993 Jun 4;236(3):341-5
references.pmid: 8102969